Genesis Biosystems, Inc. Sustainability Profile
Genesis Biosystems, Inc., headquartered in the United States, is a leading innovator in the medical device industry, specialising in advanced solutions for the healthcare sector. Founded in 2006, the company has established itself as a key player in the development of cutting-edge technologies for tissue regeneration and wound care. With a focus on products such as the innovative Genesis® System, Genesis Biosystems offers unique, evidence-based solutions that enhance patient outcomes and streamline clinical workflows. The company’s commitment to quality and innovation has earned it a strong market position, recognised for its contributions to improving healthcare delivery. As it continues to expand its operational reach, Genesis Biosystems remains dedicated to advancing the field of regenerative medicine.
DitchCarbon Score
How does Genesis Biosystems, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genesis Biosystems, Inc.'s score of 25 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genesis Biosystems, Inc.'s reported carbon emissions
In 2022, Genesis Biosystems, Inc. reported total carbon emissions of approximately 686,600 kg CO2e, comprising 404,000 kg CO2e from Scope 1 emissions and 282,600 kg CO2e from Scope 2 emissions. This data reflects a significant reduction from 2021, where Scope 1 emissions alone were reported at 533,000,000 kg CO2e. Despite these figures, Genesis Biosystems has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets through initiatives such as the Science Based Targets initiative (SBTi). The company has not publicly committed to any climate pledges or reduction initiatives at this time. Overall, while Genesis Biosystems has made strides in reducing its emissions, particularly in Scope 1, the absence of comprehensive climate commitments and targets indicates an area for potential growth in their sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 533,000,000 | 000,000 |
| Scope 2 | - | 000,000 |
| Scope 3 | - | - |
How Carbon Intensive is Genesis Biosystems, Inc.'s Industry?
How Carbon Intensive is Genesis Biosystems, Inc.'s Location?
Genesis Biosystems, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Genesis Biosystems, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
